Potential MFN impact
Reference country selection HHS provided guidance on setting benchmark pricing by considering the lowest price among a set of reference countries, defined by...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA’s policy team provides analysis and insights into global, regional and national policy issues affecting patients, the healthcare system, and the life sciences industry. CRA has a reputation for independence and rigor, benefiting from long standing relationships with most leading life sciences organizations as well as national governments and the European Commission and industry associations. Our specialist team has provided unique policy oversight for the past 20 years delivering high quality, robust analysis in a compelling fashion that is accessible to the target audience, whomever it may be.
Reference country selection HHS provided guidance on setting benchmark pricing by considering the lowest price among a set of reference countries, defined by...
A new report from the Partnership for Health System Sustainability and Resilience EU Expert Advisory Group, supported by CRA, calls for a more strategic and...
Is Going to a Private-Equity Owned Hospital Bad for Your Health? Private equity investment in health care has increased more than 20-fold—from $5 billion in...
CRA is a proud sponsor of the event. Elina Koustoumpardi is a speaker during the presentation titled “EU Commission Revision of 102 Guidelines: Impact on...